World Preview Webinar 2024
Pharma's Growth Boost

Thursday 11th July 3pm BST | 10am EST
Are you ready to look at the pharma landscape through a long-range lens?  Evaluate has just released new forecasts out to 2030.
With obesity, immuno-inflammation and oncology driving an increase in CAGR to 2030 of 7.7%, the panel will discuss what this means for the 10 top-selling therapies and the domination of the so-called ‘big drugs for big diseases’.


  • Novo and Lilly soar up the company charts, having just entered the top 10 last year. 
  • Resurgent CNS and respiratory are both prominent among most valuable pipeline candidates
  • The prescription drug market will hit $1.7 trillion.

Your Hosts:

Melanie Senior,
Author, World Preview Report
Daniel Chancellor,
VP, Norstella Thought Leadership
Paul Verdin,
SVP, Consulting & Analytics, Evaluate